Board Meeting29 Jul 2026, 04:51 pm
Vivanta Industries Approves Q1 FY27 Unaudited Financial Results
AI Summary
Vivanta Industries Ltd announced that its Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also noted disclosures of interest received from directors, declarations of independence from independent directors, and the issuance of a duplicate share certificate. Additionally, the company took note of business collaboration agreements with Qness Pharmaceuticals, the Corporate Governance Report for Q1 FY27, and the e-form DPT-3 for the financial year ended March 31, 2026. Authorizations for opening trading and demat accounts and for signing statutory documents were also approved.
Key Highlights
- Board approved unaudited standalone and consolidated financial results for Q1 FY27.
- Noted disclosures of director interests and independence declarations.
- Approved business collaboration agreements with Qness Pharmaceuticals.
- Took note of Corporate Governance Report and DPT-3 filing.
- Authorized signatories for accounts and statutory filings.
Price Impact
More from VIVANTA